Terebellum, Global Healthcare and Specialty Pharmacy Solutions Company Announces Partnership with NeurosolvTherapeutics

Terebellum, Global Healthcare and Specialty Pharmacy Solutions Company Announces Partnership with NeurosolvTherapeutics 

DUBLIN, IRELAND – October 5, 2022 –  Terebellum, the Ireland and UK-based subsidiary of AscellaHealth, a global healthcare and specialty pharmacy solutions company and a member of the AscellaHealth Family of Companies, today announced a contractual partnership with NeurosolvTherapeutics, bringing its full suite of capabilities to support the launch of Perineline,™a new patented two-part therapy for spinal cord injuries developed by NeurosolvTherapeutics that has now attained EMA Orphan Designation and is expected to revolutionize the therapeutic treatment and resulting end patient outcomes from spinal cord injuries. Terebellum’s services include strategic guidance in the pre-commercialisation stage, market access expertise, and supply chain logistics including distribution and fulfilment.

Craig Caceci, executive vice president and managing director, Terebellum, says, “Our dedicated team of highly experienced market access professionals look forward to working closely with NeursolvTherapeutics in a successful product launch that establishes optimal pricing and ensures seamless product access for patients with spinal cord injuries. This is an exciting time to be introducing a game-changing therapeutic treatment.”

NeursolvTherapeutics selected Terebellum based upon its comprehensive suite of integrated solutions, including strategic insights for early-stage products, deep bench market access expertise throughout Europe and the United States, supply chain logistics and exclusive distribution and fulfilment services.

Aidan Lynch, chairman and chief executive officer, NeursolvTherapeutics, says, “We are excited to work with Terebellum to bring Perineline™ to market globally, to allow us to proliferate and enable ethically controlled patient access under spinal cord trauma consultants. The many years of pioneering and trailblazing research developed by our Founders Ros Lynch and Aidan Lynch and Scientific Chair Dr. Jessica Kwok are bringing seismic change to the prospects for recovery of spinal cord injury patients. Terebellum’s consultative business model and collaborative approach enables us to take advantage of their thorough expertise and knowledge which are critical to the launch planning and commercialisation of Perineline™. At every step of the way, we know that we can rely upon Terebellum for key strategic insights throughout the implementation process.”